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In Vitro and In Vivo Differences in 
Murine Third complement 
component (c3) Opsonization and 
Macrophage/leukocyte responses 
to antibody-Functionalized iron 
Oxide nanoworms
Guankui Wang1, James I. Griffin1, Swetha Inturi1†, Barbara Brenneman1, Nirmal K. Banda2, 
V. Michael Holers2, Seyed Moein Moghimi3 and Dmitri Simberg1*
1 The Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Denver, Anschutz Medical Campus, 
Aurora, CO, USA, 2 Division of Rheumatology, School of Medicine, University of Colorado Denver, Anschutz Medical 
Campus, Aurora, CO, USA, 3 School of Medicine, Pharmacy and Health, Durham University, Queen’s Campus,  
Stockton-on-Tees, UK
Balancing surface functionalization and low immune recognition of nanomedicines is a 
major challenge. Opsonization with the third component of the complement protein (C3) 
plays a major role in immune cell recognition of nanomedicines. We used dextran-coated 
superparamagnetic iron oxide nanoworms (SPIO NWs) to study the effect of surface 
functionalization on C3 opsonization in mouse serum and subsequent macrophage/
leukocyte recognition in vitro as well as on intravenous injection into mice. Previously, we 
found that in mouse serum, SPIO NWs became opsonized with C3 via complement lectin 
pathway. Crosslinking the dextran shell with epichlorohydrin significantly decreased C3 
opsonization and uptake by mouse peritoneal macrophages. Crosslinked nanoworms 
(NWs) further functionalized with polyethylene glycol (PEG) or with PEG-antibody (Ab) 
(~160 IgG molecules/particle) did not show an increase in C3 opsonization and perito-
neal macrophage uptake in vitro. Following tail vein injection into mice, plain crosslinked 
NWs and PEGylated crosslinked NWs showed very low C3 opsonization and mouse 
leukocyte uptake. However, Ab-decorated crosslinked NWs showed significant C3 
opsonization and high level of complement-dependent uptake by leukocytes in mice. 
Decreasing the number of conjugated Abs to 46 IgG molecules/particle significantly 
reduced C3 opsonization and leukocyte uptake. Using fresh mouse lepirudin plasma 
rather than serum showed better correlation with C3 opsonization in vivo. The reason for 
this difference could be related to the known instability of complement classical pathway 
in mouse sera. Our data illustrate that fine-tuning in nanoparticle surface functionaliza-
tion with Abs is required to avoid excessive complement activation and complement- 
mediated immune uptake in mice, and raise issues with in vitro immunological assays of 
nanomedicines intended to mimic in vivo conditions.
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Figure 1 | The scheme of the upstream mouse complement pathways. C5a convertase and the terminal membrane attack complex pathway are not 
shown. There are three initiating complement pathways: classical, lectin, and alternative. All the pathways generate activated central complement protein 
component C3, liberating C3b, and its fixation on the pathogen (or nanoparticle) surface.
2
Wang et al. Complement Activation in Mice
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 151
inTrODucTiOn
The success of systemically and locally administered nanoma-
terials largely depends on the ability of nanosized carriers to 
efficiently evade the immune system (1). Several pathways of 
the innate immune system mediate clearance of nanoparticles 
by phagocytic cells. Complement system is an effector arm of 
the innate immune system composed of more than 30 blood 
proteins that accounts for about 5% of globulins in serum and 
is responsible for recognizing, eliminating, and destroying 
pathogens (2). The activation of complement system on foreign 
surface via lectin, classical, or alternative pathways [LP, classical 
pathway (CP), or AP, respectively] converges to cleave native 
C3 and generate a highly reactive thioester on C3b, which 
covalently attaches to reactive functional groups (e.g., hydroxyl 
and amines) on target surface (3–5). Opsonization by C3b and 
its cleavage products (iC3b, C3d) triggers particle recognition 
by leukocytes through complement receptors (6, 7), whereas 
soluble cleavage byproducts C3a and C5a are among the most 
potent anaphylatoxins and proinflammatory molecules with 
low nanomolar affinity (8). Numerous nanomaterials activate 
the complement system and become opsonized with C3 in vitro 
and in vivo (9–13).
Superparamagnetic iron oxide (SPIO) nanoparticles have 
been used as magnetic resonance imaging (MRI) contrast agents 
and also as carriers for drug delivery (14). SPIO nanoparticles 
consist of 5–8  nm magnetite–maghemite (Fe3O4 and γ-Fe2O3) 
crystalline cores coated with a polymer (15). Recently, we 
reported the synthesis of 20 kDa dextran-coated superparamag-
netic iron oxide nanoworms (SPIO NWs) with high transverse 
relaxivity r2, which makes them promising MRI contrast agents 
(16). Unfortunately, SPIO NWs potently activate complement in 
both mice and humans (17). Previously, we demonstrated that 
mouse complement activation is via LP (17), whereas human 
complement activation is predominantly via the AP (18). As 
shown in Figure 1, initiation of the LP starts with the binding of 
mannose-binding lectin (MBL)-A/C, ficolins, or collectin-11 to 
the carbohydrates on the pathogen surfaces. The binding leads to 
activation of MBL-associated serine proteases (MASPs), leading 
to formation of the complement convertase C4bC2a, cleavage of 
C3, deposition of initial C3b, and possible amplification via the 
alternative pathway convertase C3bBb. MASP-2 plays a direct 
role in formation of the complement convertase C4bC2a (19) 
whereas MASP-1 and MASP-2 indirectly activate MASP-2 (20) 
and factor D (21, 22), respectively.
Interestingly, modifying the surface dextran coating with 
epichlorohydrin (ECH) [resulting in poly-(2-hydroxypropyl 
ether) hydrogel] blocked mouse complement C3 opsonization 
and leukocyte uptake (16). At the same time, it is not clear how 
further surface functionalization of ECH-crosslinked NWs 
(hereafter CL-NWs) affects complement activation and immune 
uptake. In view of the remarkable redundancy of pathways 
responsible for immune recognition (7) maintaining the delicate 
balance between surface functionalization and stealth properties 
could be a challenging task. In particular, the effect of addition of 
targeting ligands on “stealth” nanoparticles on complement acti-
vation and immune uptake has not been investigated in depth. 
In order to understand the impact of surface functionalization of 
CL-NWs with targeting antibodies (Abs) on complement activa-
tion and immune recognition, we modified CL-NWs with a poly-
ethylene glycol (PEG) linker followed by a model anticancer Ab 
(trastuzumab). Here, we demonstrate that surface modification of 
CL-NWs that have low complement activation with trastuzumab 
can increase complement activation dependent on Ab surface 
Figure 2 | surface modification of superparamagnetic iron oxide nanoworms (sPiO nWs). (a) Representative transmission electron microscopy (TEM) 
image of SPIO NWs shows electron dense worm-like aggregates of magnetite crystals. Only the cores are visible in TEM. The scale bar is 200 nm; (B) graphic (top) 
and chemical (bottom) description of modifications of SPIO NWs. Dextran layer (yellow) was crosslinked with epichlorohydrin to form crosslinked hydrogel 
nanoworms (CL-NWs). The CL-NWs were then aminated using different concentrations of ammonium hydroxide to form CL-NWs-amine. CL-NWs-amine were 
further modified with succinimidyl valerate (SVA)-polyethylene glycol (PEG) maleimide and conjugated to thiolated antibodies (Abs); (c) the upper graph shows 
hydrodynamic size of nanoworms (NWs) measured by dynamic light scattering. The surface modifications did not significantly affect the hydrodynamic size of NWs. 
The lower graph represents the zeta potential values of NWs. The overall electric charge of CL-NWs switched from negative to positive after amination and for the 
corresponding functionalized particles.
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density, and further raise an issue of in vitro versus in vivo cor-
relation assays of immune recognition of nanoparticles.
resulTs anD DiscussiOn
effect of nanoworm (nW) Modification 
and Functionalization on c3 Opsonization 
and immune uptake in Mouse sera 
In Vitro
Dextran-coated SPIO NWs were prepared from 20  kDa dex-
tran, FeCl2, and FeCl3 by a modified Molday and MacKenzie 
precipitation protocol (23). According to transmitted electron 
microscopy (Figure  2A), nanoparticle cores contained worm-
like aggregates of iron oxide crystals. On the outside, the cores 
are covered with a shell of dextran chains (Figure 2B). Dextran 
shell was crosslinked with ECH in the presence of NaOH to yield 
hydrogel-coated CL-NWs (Figure  2B). The residual epoxides 
on CL-NWs were treated with ammonia to generate primary 
amines that were further functionalized with heterobifunctional 
maleimide (MAL)-PEG3400-succinimidyl valerate (SVA) to yield 
CL-NWs-PEG-MAL (hereafter CL-NWs-PEG; Figure  2B). 
PEG-MAL-functionalized particles were modified with thi-
olated Ab trastuzumab (Herceptin®) to yield CL-NWs-PEG-Ab 
(Figure 2B). According to size measurements (Figure 2C, top), 
the modifications did not affect the hydrodynamic diameter of 
NWs. Zeta potential values were slightly negative for SPIO NWs 
and CL-NWs, but expectably became positive for CL-NWs 
treated with ammonia and the corresponding functionalized 
particles (Figure 2C, bottom). Quantitative measurements (see 
Materials and Methods) showed that on average there were ~160 
IgG molecules per each CL-NWs-PEG-Ab nanoparticle.
In order to confirm the role of the LP as the inciting pathway 
of complement activation in mouse serum, SPIO NWs were 
incubated in validated sera obtained from mice deficient for 
various complement pathways (Figure 1), washed, and analyzed 
for mouse C3 in Western blotting (the same amount of particles 
were used in the assay and loaded on the gel). According to 
Figure 3, SPIO NWs showed strong C3 (C3b/iC3b) opsonization 
in wild type (WT) mouse serum, whereas the opsonization was 
blocked in sera deficient for MBL-A/C (LP) and MBL-A/C/factor 
D (LP and AP). In addition, C3 opsonization was blocked in sera 
deficient for factor D and factor B (AP). These data confirm that 
complement is triggered by MBL/MASP-2-dependent LP activa-
tion, whereas the AP provides the amplification loop.
Next, we compared the efficiency of C3 opsonization of 
CL-NWs, CL-NWs-PEG, and CL-NWs-PEG-Ab with SPIO 
NWs. Particles were incubated in normal mouse serum or 
in sera deficient for the LP factors MBL-A/C and MASP-2, 
washed, loaded in the same amount on a gel, and analyzed by 
Western blotting. All CL-NWs formulations showed 80–85% 
decrease in C3 opsonization in normal serum compared with 
SPIO NWs (Figures  4A,B). Moreover, CL-NWs formulations 
incubated in MBL-A/C-deficient and MASP-2-deficient sera 
(Figures  4A,B) showed further reduction of C3 opsonization. 
These data demonstrate that crosslinking predominantly blocks 
complement activation and functionalization of CL-NWs with 
PEG or PEG-Ab does not enhance complement activation in 
mouse serum.
C3 is the critical opsonin mediating the uptake of foreign 
pathogens by macrophages and leukocytes (2). We tested 
whether functionalization of CL-NWs affected the uptake by 
non-activated mouse peritoneal macrophages in mouse serum. 
As shown in Figure S1 in Supplementary Material, over 70% of 
freshly isolated cells showed expression of CD11b (receptor for 
iC3b) and F4/80 (a macrophage marker). SPIO NWs, CL-NWs, 
CL-NWs-PEG, and CL-NWs-PEG-Ab were preincubated in 
normal (WT) mouse serum for 15 min, and then added to the 
Figure 3 | Mechanisms of complement c3 opsonization by 
non-modified superparamagnetic iron oxide nanoworms (sPiO nWs). 
Detection of C3 (mostly in iC3b form due to appearance of α2′ fragment at 
~40 kDa) bound to SPIO NWs in mouse sera. Nanoworms became 
opsonized in control (wild type) sera but not in sera deficient for mannose-
binding lectin (MBL), MBL/factor D, factor D, and factor B, suggesting that 
the LP is the initiating route and the AP turnover is responsible for 
amplification. Note that beta-chain of mouse C3 is not highly detectable with 
this antibody.
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cells at 0.1 mg/mL Fe for 6 h. According to Prussian blue staining 
and quantification (Figures  5A,B, see Materials and Methods 
for details), SPIO NWs showed highly intense cytoplasmic 
accumulation of iron. CL-NWs showed 80% less uptake than 
SPIO NWs. The functionalized CL-NWs had the same level of 
residual uptake as non-functionalized CL-NWs, suggesting that 
PEG and Ab modifications do not trigger the uptake in mouse 
serum. Incubation of SPIO NWs and all CL-NWs formulations 
in C3-deficient mouse serum resulted in a complete blockade of 
the residual uptake of CL-NWs formulations (Figures  5A,B), 
suggesting that the uptake of SPIO NWs and the residual uptake 
of CL-NW formulations are mediated through C3 opsonization.
effect of cl-nWs Functionalization on c3 
Opsonization and immune uptake In Vivo
Previously, we demonstrated that complement C3 mediates the 
uptake of SPIO NWs by blood leukocytes in mice (10). SPIO 
NWs, CL-NWs-PEG, and CL-NWs-PEG-Ab were injected 
intravenously into mice at 5  mg Fe per kg body weight, 
recovered from blood 5  min post-injection using a magnetic 
column [in this process, both free particles and magnetically 
labeled leukocytes were enriched (10)], and analyzed for C3 
opsonization and leukocyte uptake as shown in Figure 6A. We 
used a previously established (10, 16–18) dot-blot procedure 
to compare the levels of C3 opsonization on NWs. According 
to Figure S2 in Supplementary Material, C3 dot-blot assay cor-
relates with C3 Western blot for determining the levels of C3 on 
particles. According to Figures 6B,C, SPIO NWs showed high 
level of C3 opsonization in vivo and leukocyte uptake. Similar to 
in vitro serum results, CL-NWs-PEG showed less than 10% of 
C3 compared to SPIO NWs, and low level of leukocyte uptake. 
Non-modified CL-NWs also showed low level of in  vivo C3 
opsonization and leukocyte uptake (Figure S3 in Supplementary 
Material), confirming our previous findings (10). However, in 
contrast to in vitro measurements, CL-NWs-PEG-Ab decorated 
with ~160 IgG/particle showed 66% of C3 opsonization of 
SPIO NWs and high leukocyte uptake in vivo (Figures 6B,C). 
Injection of CL-NWs-PEG-Ab into C3 knockout (KO) mice that 
completely lacks C3 abolished the leukocyte uptake (Figure 6C). 
These data suggest that conjugation of IgG on the particles 
triggered complement activation and complement-dependent 
immune uptake that was not detected using in  vitro assays in 
mouse serum.
Surface immobilized Abs and immune complexes, however, 
are known to trigger complement via the CP (24). It is likely 
that in vivo Ab-functionalized NWs trigger the CP. At least two 
surface-bound IgG molecules must be bridged by a C1q molecule 
before activation of the CP can proceed. In order to test whether 
the number of IgG per particle can control complement activa-
tion in vivo, we synthesized CL-NWs-PEG-Ab bearing different 
Ab densities and tested their C3 opsonization and leukocyte 
uptake in  vivo. According to Figures  7A,B, CL-NWs-PEG-Ab 
with 1 IgG/particle, 8 IgG/particle, and 46 IgG/particle showed 
significantly lower levels of in vivo C3 opsonization (17, 3, and 
22% of SPIO NWs, respectively) and leukocyte uptake than 
CL-NWs-PEG-Ab with 160 IgG/particle. However, the observa-
tion of higher C3 opsonization with CL-NW-PEG-Ab bearing 
a single Ab molecule compared with CL-NW-PEG-Ab with 
8 IgG/particle is intriguing. The reason for this is unclear, but 
this suggests the involvement of other in vivo factors regulating 
complement activation and fixation and therefore requires fur-
ther investigation. Nevertheless, these experiments suggest that 
decreasing surface density of Ab molecules can suppress comple-
ment activation and immune cell recognition in vivo. CL-NWs-
PEG-Ab with 8 trastuzumab/particle showed specific uptake by 
HER2/neu + human breast cancer cell line SKBR-3 (Figure S4 
in Supplementary Material), suggesting that the immobilized Ab 
is functional on the nanoparticles and therefore may bind to its 
designated target in vivo.
Next, we sought an explanation to the observed lack of 
complement activation by CL-NWs-PEG-Ab (160 IgG/particle) 
in serum (Figure 4) versus in vivo. Previous evidence suggested 
that the CP of the complement system is unstable in mouse sera 
(25–27) and, furthermore, starts losing its activity at room tem-
perature (RT) and even during −70°C storage (26). Accordingly, 
blood clotting procedures and serum isolation steps could trigger 
loss of CP activity and explain poor C3 opsonization in mouse 
serum through this pathway. To address this, we repeated the 
experiments with fresh mouse plasma using recombinant hiru-
din (lepirudin) as anticoagulant. Lepirudin is the only known 
anticoagulant that does not interfere with complement activa-
tion. The results shown in Figure  7C demonstrate that SPIO 
NWs potently activate complement in fresh lepirudin plasma. 
CL-NWs-PEG showed only 26% of C3 opsonization of SPIO 
NWs in plasma. At the same time, CL-NWs-PEG-Ab (1 IgG/
particle), CL-NWs-PEG-Ab (46 IgG/particle), and CL-NWs-
PEG-Ab (160 IgG/particle) showed high C3 opsonization 
A B
Figure 5 | Peritoneal macrophage uptake of superparamagnetic iron oxide nanoworms (sPiO nWs) and cl-nWs in mouse serum is complement 
dependent. (a) Prussian blue staining of iron uptake by cells. The peritoneal macrophages were incubated with SPIO NWs, CL-NWs, CL-NWs-polyethylene glycol 
(PEG), and CL-NWs-PEG-Ab (from left to right) in the presence of wild type (WT) serum (first row) or C3-deficient [knockout (KO)] serum (second row). All images 
were taken at 20× magnification and cropped to the same extent. Most of the Prussian blue stain is clearly intracellular as shown in the magnified insert;  
(B) quantification of Prussian blue staining of iron in cells. The uptake of CL-NWs was 85% decreased compared with SPIO NWs (n = 20; p < 0.0001). The uptake 
of nanoworms C3 KO serum was significantly less than in WT sera (n = 20; p < 0.0001). For quantification and statistical analysis, see Section “Materials and 
Methods.”
A B
Figure 4 | crosslinked dextran blocks lectin pathway activation in mouse sera. (a) Detection of C3 bound to superparamagnetic iron oxide nanoworms 
(SPIO NWs) and CL-NWs in a wild type (WT) mouse serum and in serum deficient for lectin pathway factors MBL-associated serine protease (MASP)-2 and 
mannose-binding lectin (MBL)-A/C. The lanes represent: 1, SPIO NWs; 2, CL-NWs; 3, CL-NWs-polyethylene glycol (PEG); and 4, CL-NWs-PEG-Ab (160 IgG/
particle). Left gel = WT serum. Complement opsonization was decreased for all CL-NWs formulations. C3 opsonization was blocked for all groups of nanoworms; 
(B) densitometry analysis of C3 α′1-chain. All CL-NWs formulations showed >80% decrease of C3 binding in WT sera compared to SPIO NWs. The residual 
complement activation of CL-NWs and functionalized CL-NWs is via the lectin pathway.
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compared to SPIO NWs [46, 88, and 110% of C3 opsonization 
to SPIO NWs, respectively (Figure 7C)]. Therefore, the results 
in plasma are better correlated with C3 opsonization in vivo than 
in serum. At the same time, the relative levels of C3 opsoniza-
tion were much higher in plasma than in vivo. Thus, plasma C3 
opsonization of CL-NWs-PEG-Ab (46 IgG/particle) was 88% of 
SPIO NWs (Figure 7C), whereas in vivo C3 opsonization level 
of the same particle was 22% of SPIO NWs (Figure 7A). These 
discrepancies may be related to the dynamic differences in NW 
protein corona in vitro versus in vivo conditions in regulating 
complement activation (28). In summary, these data suggest that 
C3 assay in plasma is a better predictor of in vivo complement 
activation for Ab-modified particles than in serum, but at the 
same time the opsonization efficiency in  vitro does not fully 
correlate with the efficiency in vivo, likely due to differences in 
dynamics of protein interaction, corona formation, and comple-
ment activation.
Our studies demonstrate that surface modifications of 
nanoparticles have profound effect on complement C3 opsoniza-
tion and the resultant immune uptake. Previous studies using 
PEGylated liposomes and nanoparticles showed loss of stealth 
properties after tethering of Abs and ligands (29–31) and that 
surface functionalization affects the cellular uptake (32–34). 
Nevertheless, the mechanistic studies explaining the effect of sur-
face functionalizations were lacking and our study demonstrates 
for the first time the balance between surface functionalization, 
complement activation, and immune cell uptake. Immune 
system, including the complement system, is generally redun-
dant, meaning that multiple pathways are utilized to recognize 
foreign epitopes. While the exact pathway by which surface Ab 
A B C
Figure 7 | Decreasing complement activation and leukocyte uptake in vivo by controlling number of antibodies per particle. (a) Complement 
opsonization in vivo of CL-NWs prepared with reduced number of IgG molecules per particle. Superparamagnetic iron oxide nanoworms (SPIO NWs) were used as 
a reference (100%) of C3 levels. Complement opsonization was significantly decreased for CL-NWs-polyethylene glycol (PEG)-Ab with 1 IgG/particle, 8 IgG/particle, 
and 46 IgG/particle compared to SPIO NWs (n = 3; p < 0.0001); (B) leukocyte uptake in vivo shows that CL-NWs-PEG-Ab with low number of IgG per particle 
show much lower leukocyte uptake than CL-NWs-PEG-Ab (160 IgG/particle, compared to Figure 6c); (c) complement C3 opsonization in fresh plasma in vitro. 
Particles were incubated in fresh plasma obtained with lepirudin as anticoagulant. C3 opsonization for CL-NWs-PEG-Ab was much higher in plasma than in serum 
(Figure 3) but also much higher than in vivo, suggesting that in vitro opsonization assay in plasma, while more representative than serum, still does not fully correlate 
with in vivo opsonization (p = 0.0001 for 46 IgG/particle and 160 Ab/particle, respectively).
Figure 6 | conjugated antibodies trigger complement activation and leukocyte uptake in vivo. (a) Nanoworms (NWs) were injected intravenously into 
mice and recovered from the blood 5 min post-injection. MIDI Max magnetic column trapped both free NWs and magnetically labeled leukocytes that took up NWs; 
(B) NWs were loaded on nitrocellulose membrane (same amount of Fe for all formulations) and analyzed for mouse C3. The image shows the C3 dot blot and the 
graph shows quantitative image analysis. There was no complement opsonization of CL-NWs-polyethylene glycol (PEG) but significant opsonization of CL-NWs-
PEG-Ab (160 IgG/particle); (c) microscopic images of slides after cytospin (nuclear Hoechst stain shows nucleated leukocytes) that were eluted from magnetic 
column. One representative cropped microscopic field is shown for each formulation. Each dot represents a leukocyte. A significant number of leukocytes took up 
particles after injection of superparamagnetic iron oxide nanoworms (SPIO NWs) and CL-NWs-PEGs-Ab. The uptake by leukocytes was abolished when CL-NWs-
PEG-Ab were injected into C3-deficient mouse (lower right).
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triggers complement activation needs to be elucidated further, 
the need to control complement activation via the number of 
conjugated Abs is an important aspect in the design of targetable 
nanomedicines.
Importantly, our study suggests that complement activation 
via surface immobilized Ab could be missed using in  vitro 
assays in murine sera. Therefore, valid complement assays of 
nanoparticles should be used, at the very least using lepirudin 
plasma in vitro, but preferably in the animal in vivo. The lack 
of correlation between in vitro and in vivo assays adds to the 
lack of correlation in pathways of complement activation in 
mice and humans (10, 17). Mouse models are widely used in 
preclinical studies of biodistribution and toxicity of drug deliv-
ery systems. In addition, complement-mediated mechanisms 
of immune uptake are likely similar in mice and humans (10). 
Despite these, any extrapolation of mouse data on the immune 
recognition of nanocarriers to humans should be interpreted 
with caution.
7Wang et al. Complement Activation in Mice
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MaTerials anD MeThODs
Materials
All reagents used for NW synthesis including Fe salts and 20 kDa 
(range 15–25 kDa) dextran were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). Cell culture media were purchased from 
Corning Life Sciences (Corning, NY, USA). Copper grids (300 
mesh) were purchased from Electron Microscopy Sciences 
(Hatfield, PA, USA). Anti-HER2 Ab Herceptin® was gener-
ously donated by the Pharmacy of the University of Colorado 
Cancer Center, Anschutz Medical Campus. Anti-mouse anti-C3 
Ab was purchased from MP Biomedicals (Solon, OH, USA). 
IRDye 800CW-labeled secondary Abs were purchased from 
Li-COR Biosciences (Lincoln, NE, USA). Purified anti-mouse/
human CD11b Ab was purchased from BioLegend (San Diego, 
CA, USA). Anti-mouse F4/80 Ab was purchased from Caltag 
Medsystems Ltd. (Buckingham, UK). Hoechst 33342 for nuclei 
staining was purchased from Thermo Fisher Scientific (Waltham, 
MA, USA). The Abs for each experiment were diluted accord-
ing to the recommendations from manufacturers. Mouse sera 
deficient for C3, MBL-A/C, MBL-A/C/factor D, and factor B 
were collected from mice that were bred in an animal vivarium at 
the University of Colorado Anschutz Medical Campus according 
to the Institutional Animal Care and Use Committee (IACUC) 
approved breeding protocol. Recombinant human hirudin 
(lepirudin, catalog No. ACM154) was obtained from Aniara 
Diagnostica, LLC (West Chester, OH, USA), reconstituted in water 
to 1 µg/µL (160 antithrombin units/μL), and stored aliquoted at 
−80°C. Lepirudin anticoagulated plasma (hereafter plasma) was 
obtained by collecting blood through the cardiac puncture (final 
lepirudin concentration 3–4 µg/mL) and centrifuging the tube at 
2,000 g for 15 min.
synthesis of sPiO and crosslinked 
nanoworms (cl-nWs)
Nanoworms were synthesized by a modified one-pot Molday and 
MacKenzie (23) precipitation method as described earlier (16). 
Nanopure water (30 mL) was de-oxygenated with nitrogen gas 
and used to dissolve 6 g dextran (molecular weight 20 kDa, Sigma-
Aldrich), 1.26 g Fe(III) chloride, and 0.498 g Fe(II) chloride in a 
round bottom flask. Next, 2.4 mL of cold 25% (v/v) ammonium 
hydroxide (NH4OH) was slowly added to the mixture of dextran 
and iron salts under nitrogen atmosphere with rapid stirring on 
ice. After formation of NWs, the mixture was heated at 80°C with 
stirring. After cooling, SPIO NWs were purified overnight using a 
20 kDa dialysis cassette (Thermo Fisher Scientific, Waltham, MA, 
USA) against double distilled water to remove free dextran. The 
particles were chemically crosslinked using 1-chloro-2, 3-epoxy-
propane (ECH) with sodium hydroxide as described before (16). 
SPIO NWs and CL-NWs were filtered through a 0.45 μLm-pore 
filter (Millipore, Billerica, MA, USA) prior to use.
surface Modifications of cl-nWs
CL-NWs were aminated by adding different concentrations of 
ammonium hydroxide at 4°C overnight to form CL-NWs-NH2 
and dialyzed for 24  h to remove free NH4OH. For the Ab 
conjugation, MAL-PEG-SVA (MAL-PEG-SVA, Laysan Bio) 
was reacted at excess with CL-NWs-NH2 at RT for 30  min to 
form CL-NWs-PEG-MAL or CL-NWs-PEG. Anti-HER2 Ab 
Herceptin® was reacted in the last step with MAL-PEG to form 
CL-NWs-PEG-Ab. NWs were purified by ultracentrifugation at 
55,000  rpm, filtered through a 0.45  µm pore filter, and finally, 
stored in Dulbecco’s phosphate-buffered saline (DPBS) at pH 7.4 
before use.
characterization of nWs
Transmission electron microscopy imaging was conducted to 
visualize the NWs using FEI Tecnai Spirit BioTwin electron micro-
scope (Electron Microscopy Facility at the University of Colorado 
Boulder) at a 100 kV working voltage. Size measurements were 
done in DPBS and zeta potential measurements were done in 0.1× 
DPBS at RT using a Zetasizer Nano ZS (Malvern Instruments 
Ltd., Malvern, UK). The intensity-weighted size distribution peak 
value was used to report hydrodynamic diameters of the NWs. 
To quantify the Ab on the NWs, known amount of CL-NWs-
PEG-Ab (0.2 µg Fe) was applied in triplicates onto a 0.2 µm pore 
nitrocellulose membrane (Bio-Rad). Standard dilutions of free 
trastuzumab were also applied onto the membrane to generate 
a standard curve. The membrane was blocked with 5% (w/w) 
non-fat dry milk in PBS-T (DPBS with 0.1% Tween® 20) for 1 h 
at RT and probed with IRDye 800CW-labeled antihuman Ab. The 
membrane was scanned with Odyssey infrared imager (Li-COR 
Biosciences, Lincoln, NE, USA). The integrated dot intensity 
in the scanned images was determined from 16-bit grayscale 
images using ImageJ software and plotted using Prism 6 software 
(GraphPad Software, Inc., La Jolla, CA, USA) to determine the 
number of Ab molecules per spot using the calibration curve. 
Concentration of particles per milligram Fe was determined 
with NanoSight (Malvern Instruments) and Fe concentration was 
determined with ferrozine iron assay as described before (16). 
The number of Abs per NW was determined after dividing the 
number of Abs per spot by the number of NWs per spot.
Protein Binding assay
Superparamagnetic iron oxide and CL-NWs (10 µL of 1 mg/mL) 
were incubated with 30 µL of mouse serum or lepirudin plasma 
for 15 min at RT. At the end of incubation, particles were washed 
three times with 1× PBS by centrifugation at 100,000  g at 4°C 
using Beckman Optima TLX ultracentrifuge. The pellets were 
resuspended in 20 µL DPBS, and the concentration of Fe in each 
sample was normalized with ferrozine iron assay as described 
before (16). For complement C3 western blot, 10 µL aliquots were 
used for gel electrophoresis. The samples were mixed with loading 
buffer [denaturing buffer containing 100 mM Tris, 20% glycerol, 
4% SDS, 5% (v/v) 2-mercaptoethanol, 0.02% bromophenol blue] 
and then boiled at 95°C for 5 min. After cooling for 5 min, the 
samples and marker proteins (Precision Plus Proteins Dual Color 
Standards from Bio-Rad) were loaded onto Mini-PROTEAN 
TGX Gels (Bio-Rad, Hercules, CA, USA) and separated at 50 V 
for 5 min and then 100 V for 90 min. Gels were then transferred 
to nitrocellulose membranes using the Mini Trans-Blot cell 
system overnight at 50 V at 4°C. For C3 dot blot, 2 µL aliquots 
were applied in triplicates onto a nitrocellulose membrane. 
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The  membranes were blocked using 5% non-fat dry milk in 
DPBS-T (DPBS with 0.1% Tween® 20) at RT for 1 h, probed with 
corresponding primary Abs at RT for 1 h, followed by washing 
the membranes 3× with DPBS-T, and finally, 1  h incubation 
with the corresponding IRDye 800CW-labeled secondary Abs 
against the primary Ab species (see Materials). The membranes 
after immunoblotting were visualized using an Odyssey infrared 
imager. The integrated dot intensity in the scanned images was 
quantitatively analyzed using ImageJ software and plotted with 
Prism 6 software as described above.
uptake of nWs In Vitro, Prussian Blue 
staining, and Quantification
Human breast cancer cell line SKBR-3 cells were maintained 
in McCoy’s 5A medium (ATCC) supplemented with 10% fetal 
bovine serum. Mouse peritoneal macrophages were obtained 
by peritoneal lavage with 5 mL ice cold PBS, post-mortem. For 
experiment, cells were plated into 96-well plate. For uptake 
experiments, NWs were preincubated for 15 m with WT mouse 
sera or C3 KO sera and added at 0.1 mg/mL Fe concentration to 
cells for 6 h. After the incubation, cells were washed using DPBS 
for three times, fixed in 4% paraformaldehyde at 4°C overnight, 
and then stained using Prussian blue for 1  h. Prussian blue 
staining is the standard method for detecting iron in cells and 
tissues, and has been extensively used for detecting uptake of 
iron oxide nanoparticles by our group and others (35, 36). The 
method is based on formation of insoluble, blue colored coor-
dination complexes between Fe3+ and potassium ferrocyanide. 
Maghemite crystals of SPIO contain both Fe3+ and Fe2+, and the 
surface of crystals is always oxidized to Fe3+, so the complete 
degradation of nanoparticles is not required for the staining 
to work. In order to quantify the blue color of the complexes 
inside the cells, TIFF RGB images of stained cells were acquired 
with a Nikon Eclipse E600 microscope using same exposure 
and magnification. The images were combined into a gallery 
with Adobe Photoshop and color balance was adjusted with a 
Level tool to make the cell-free area white. The gallery image 
was exported into ImageJ, converted into YUV color space, and 
thresholded for blue and green components using a Threshold 
Color plugin. Then, the image was converted into a 16-bit gray 
scale and inverted. The background was completely subtracted 
with a Math Subtraction tool. A ROI was drawn around each 
cell and integrated pixel density was measured. The data were 
plotted as means and SD using Prism software. An average of at 
least 20 cells was used.
nanoparticle uptake In Vivo
Wild type and C3−/− mice (Jax Laboratories: B6.129S4-C3tm1Crr/J) 
were bred in house according to the approval by University of 
Colorado Animal Protocol Committee. NWs were injected as a 
5 mg/kg bolus via tail vein into WT and C3 KO mice (8 weeks 
of age, females). Following the injection (5  min), mice were 
sacrificed and the blood was drawn via cardiac puncture using 
heparin as anticoagulant. Blood was applied on Miltenyi Mini 
MACS magnetic column (Miltenyi Biotech) and the trapped cells 
and particles were washed extensively with PBS. The particles and 
magnetic leukocytes were then eluted from the column. The cells 
were pelleted with tabletop Eppendorf centrifuge and the particles 
in the supernatant were further concentrated with ultracentrifuge 
for C3 dot-blot assay. The cell pellet was resuspended in 200 µL 
PBS and the cells were concentrated on slides using Shandon 
Cytospin 4 centrifuge (Thermo Fischer), fixed with 10% (v/v) 
formalin in PBS, and stained with Hoechst dye (Thermo Fischer) 
to enable leukocyte nuclei visualization. The images were taken 
with Nikon Eclipse E600 fluorescent microscope using DAPI 
filter at low (40×) magnification.
statistical analysis
The statistical analysis was performed using Prism 6 software. The 
differences between means of experimental groups were analyzed 
using a two-tailed parametric t-test assuming 95% confidence 
interval. Data shown as means ± SD. Differences in all data are 
shown as *p < 0.05; ***p < 0.001; ****p < 0.0001.
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